Guardant Health reported Q1 2026 revenue of $301.7 million, up 48% year over year, and increased its full-year guidance to $1.30 billion to $1.32 billion. The ramp was driven by continued growth in minimal residual disease testing and expanding oncology test volumes. In the quarter, oncology revenue rose 36% to $205.0 million on a 47% increase in oncology test volumes to 86,000. Guardant also cited growth in biopharma and data revenue and highlighted upgrades to its Guardant360 Tissue assay that include whole-transcriptome RNA testing, which it expects to act as a volume catalyst. Guardant noted it submitted data packages to CMS’s MolDx program across breast cancer surveillance, immunotherapy monitoring, and chemotherapy monitoring. Management said each submission could represent a reimbursement catalyst, while the fastest-growing product, Reveal, more than doubled volumes year over year.